In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Monogram Biosciences Inc.

Division of Laboratory Corp. of America Holdings
www.monogrambio.com

Latest From Monogram Biosciences Inc.

Siemens’ Companion Dx Deals Address Pharma’s Interest In Multiple Technologies

Separate deals with Viiv Healthcare and gene therapy specialist Tocagen illustrate the increasing emphasis on application of multiple technologies toward the development of companion diagnostics, as pharma strives to determine how best to assure market access to its targeted drugs.

BioPharmaceutical Medical Device

Siemens’ Companion Dx Deals Showcase Multiple Technologies, Improve Market Access

Siemens has joined the ranks of companies offering services to pharma to develop companion diagnostics, with the concurrent announcements in February of separate deals with Viiv Healthcare and gene therapy specialist Tocagen. In different ways, the transactions illustrate the increasing emphasis on application of multiple technologies toward the development of companion diagnostics, as pharma strives to determine how best to assure market access to its targeted drugs.

BioPharmaceutical Medical Device

Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover news from the TAVI space, ConforMIS’ customized knee implants, and Siemens’ recent companion diagnostic dealmaking.

Medical Device Deals

Despite Celgene's Abraxane Stock, Trading Earn-Outs Is The Exception Not The Rule

Though Abraxane (paclitaxel) is now part of Celgene Corp.'s growing oncology portfolio, you don't need Celgene stock to invest in its newest product, a reformulation of the generic chemotherapy that's approved to treat metastatic breast cancer. As part of Celgene's cash-and-stock $2.9 billion acquisition of Abraxis BioScience Inc. Celgene deferred at least $650 million in potential payments to Abraxis shareholders, plus royalty payments tied to Abraxane sales. Unlike most earn-out-laden deals, however, the contingency value rights, or CVRs, for the earn-outs have been securitized and now trade under the ticker CELGZ. Despite potential advantages - tradeable CVRs let shareholders bet on the success or failure of specific assets, for instance - these investment vehicles are still a rarity in the marketplace.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • ViroLogic Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Laboratory Corp. of America Holdings
  • Senior Management
  • William D Young, Chmn. & CEO
    Alfred G Merriweather, SVP, CFO
    Michael G Vicari, VP, Sales
    Christos S Petropoulos, PhD, VP, R&D, Virology & CSO
  • Contact Info
  • Monogram Biosciences Inc.
    Phone: (650) 635-1100
    345 Oyster Pt. Blvd.
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register